Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Bologna – page 72

906 clinical trials in Bologna, Italy across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bologna at a glance
906
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

906 trials in Bologna

Open in trial search

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Zilovertamab Vedotin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zilovertamab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Conjunctivitis allergic

Not recruiting

Study on Ketotifen Eye Drops for Treating Seasonal Allergic Conjunctivitis in Patients

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ketotifen Hydrogen Fumarate
  • Sponsor:Genetic S.p.A.

Neoplasm

Not recruiting

Study of CFT1946 alone and with trametinib or cetuximab in patients with BRAF-V600 mutant solid tumors who have received standard treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:C4 Therapeutics Inc.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Parkinson's disease

Not recruiting

Study on BIA 28-6156 for Parkinson's Disease in Patients with GBA1 Gene Variant

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:5,7-Dimethyl-N-((1R,4R)-4-(Pentyloxy)Cyclohexyl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide
  • Sponsor:Bial R&D Investments S.A.

Mantle cell lymphoma+2

Not recruiting

Study on KTE-X19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma Responding Partially to Ibrutinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fludarabine
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Hepatocellular carcinoma

Not recruiting

Study of Pembrolizumab as Additional Treatment for Patients with Liver Cancer (Hepatocellular Carcinoma) After Surgery or Local Ablation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Focal segmental glomerulosclerosis

Not recruiting

Study on the Effectiveness and Safety of DMX-200 with Losartan in Adults with Focal Segmental Glomerulosclerosis

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azilsartan Medoxomil
  • Sponsor:Dimerix Bioscience Pty Limited

Diffuse large B-cell lymphoma refractory+1

Not recruiting

Study on the Safety and Effectiveness of ALLO-501A and ALLO-647 for Adults with Relapsed or Refractory Large B-Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ALLO-501A
  • Sponsor:Allogene Therapeutics Inc.

Dermatitis atopic

Not recruiting

Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Open angle glaucoma+2

Not recruiting

Study on the Effectiveness of Citicoline Eye Drops for Visual Field Preservation in Patients with Open Angle Glaucoma

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Citicoline Sodium
  • Sponsor:Omikron Italia S.r.l.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Bologna

What the registry says about research in the country

01 Hematological Disorders

Innovative research focusing on Immune Thrombocytopenia and various forms of blood cancers including Acute Myeloid Leukemia and Multiple Myeloma. These trials aim to evaluate novel therapeutic approaches and combination treatments.

  • Blood Disorders
  • Leukemia Research
  • Immunology Studies

Studies include evaluation of new compounds and their safety profiles in treating various blood-related conditions.

02 Gastrointestinal Research

Comprehensive studies on inflammatory bowel conditions, focusing on Crohn's Disease and Ulcerative Colitis. Research aims to develop more effective treatments for patients with moderate to severe disease activity.

  • Inflammatory Bowel Disease
  • Treatment Response
  • Disease Management

Trials evaluate both induction therapy and long-term treatment options for gastrointestinal conditions.

03 Neurological Conditions

Investigation of treatments for sleep disorders including Narcolepsy and Idiopathic Hypersomnia, along with research into Chronic Inflammatory Demyelinating Polyneuropathy.

  • Sleep Disorders
  • Neurological Diseases
  • Treatment Safety

Focus on developing safer and more effective therapies for various neurological conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.